enigma
factor
viii
immunogen
remain
ever
pertin
treatment
hemophilia
develop
neutral
antibodi
therapeut
protein
patient
like
depend
appropri
activ
innat
immun
respons
shortli
follow
antigen
encount
understand
import
immunolog
synaps
remain
illdefin
review
examin
three
distinct
factor
contribut
fate
factor
viii
almost
immedi
infus
characterist
protein
cell
microenviron
propos
continuum
clearanc
antigen
present
facilit
remov
fviii
circul
lead
either
toler
immun
mutat
affect
qualiti
quantiti
factor
viii
fviii
manifest
hemophilia
ha
sever
congenit
bleed
disord
affect
male
sever
diseas
invers
correl
residu
activ
fviii
rang
mild
activ
moder
sever
left
untreat
individu
ha
suffer
spontan
prolong
bleed
episod
lead
increas
mortal
morbid
modern
advanc
medicin
render
patholog
manag
via
intraven
infus
fviii
either
plasmaderiv
pdfviii
recombin
rhfviii
sourc
treatment
administ
either
prophylact
ondemand
typic
begin
child
becom
mobil
month
trigger
symptom
bruis
joint
bleed
sever
complic
ha
treatment
develop
neutral
antibodi
fviii
term
inhibitor
patient
sever
ha
inhibitor
typic
develop
exposur
day
fviii
month
age
immun
system
fulli
develop
render
treatment
virtual
inefficaci
interestingli
fviii
inhibitor
also
preval
patient
mild
moder
ha
incid
exposur
day
reach
exposur
day
repeat
exposur
fviii
regimen
known
immun
toler
induct
proven
method
erad
inhibitor
howev
expens
alway
success
ultim
increas
morbid
healthcar
cost
associ
inhibitor
underlin
urgenc
identifi
strategi
would
prevent
develop
mechan
underli
variabl
inhibitor
develop
unclear
abil
reliabl
predict
whether
patient
develop
inhibitor
current
exist
howev
mani
factor
associ
increas
risk
simplifi
method
conceptu
risk
inhibitor
develop
binari
classif
patient
race
famili
histori
fviii
mutat
polymorph
mhcii
tnf
treatmentassoci
variabl
frequenc
exposur
type
fviii
concentr
concurr
infectioninflamm
realiti
howev
like
delic
complex
interact
set
variabl
influenc
immun
respons
decreas
fviiiinhibitori
activ
hivposit
ha
patient
taught
us
mechanist
fviii
immun
respons
like
involv
aspect
classic
celldepend
respons
fviii
intern
subsequ
degrad
profession
apc
follow
present
fviii
peptid
majorhistocompat
molecul
mhc
class
ii
correspond
peptidespecif
cell
process
fviii
immun
complic
associ
von
willebrand
factor
vwf
circul
interact
exert
domin
influenc
biodistribut
protein
character
strong
correl
endogen
vwf
level
infus
fviii
halflif
potenti
mediat
mask
fviii
region
protect
prematur
proteolysi
activ
protein
c
like
modul
receptormedi
endocytosi
therefor
distinct
must
made
regard
continuum
clearanc
antigen
present
plasma
protein
review
examin
paradigm
well
assess
pivot
earli
step
lead
fviii
immun
three
level
protein
cellular
microenviron
fig
protein
circul
bloodstream
tertiari
structur
posttransl
modif
provid
bind
motif
vari
affin
differ
receptor
mediat
proteolysi
clearanc
other
influenc
present
fviii
vwf
heavili
glycosyl
protein
evid
suggest
nand
olink
glycosyl
influenc
secret
clearanc
role
glycan
structur
previous
review
glycom
analysi
nlink
olink
predict
glycosyl
site
plasma
deriv
vwf
reveal
estim
uniqu
nglycan
structur
uniqu
oglycan
structur
underlin
variabl
complex
understand
role
sugar
glycom
fviii
yet
investig
similar
detail
fviii
contain
total
potenti
nlink
glycosyl
site
shown
occupi
fig
site
potenti
olink
glycosyl
elucid
least
olink
glycan
exclus
b
domain
cap
sialic
acid
residu
glycan
expos
fviii
complex
vwf
remain
unclear
interestingli
studi
use
bdomain
delet
rhfviii
report
differ
clearanc
immunogen
despit
delet
substanti
segment
highli
glycosyl
protein
find
suggest
glycan
outsid
b
domain
may
play
domin
role
regul
clearanc
immunogen
mass
spectrometri
analysi
sugar
chain
pdfviii
rhfviii
reveal
presenc
high
mannoseand
complextyp
residu
protein
two
sourc
fviii
similar
halfliv
primat
model
two
high
mannos
glycan
structur
remain
conserv
among
recombin
nativ
protein
locat
domain
respect
glycan
structur
protein
like
contribut
stabil
fold
fviii
pair
vwf
particular
mannos
glycan
fviii
b
domain
contribut
er
traffick
protein
fold
via
bind
mutat
link
combin
factor
v
fviii
defici
contrast
expos
glycan
also
implic
clearanc
immunogen
discuss
subsequ
section
review
fig
three
level
potenti
modul
fviii
innat
immun
fviiivwf
complex
contain
characterist
protein
level
influenc
endocytosi
surfac
glycosyl
element
protein
addit
influenc
shear
forc
vwf
fviii
innat
immun
dictat
receptor
correspond
cell
type
lead
protein
degrad
present
peptid
mhc
class
ii
subsequ
develop
adapt
immun
respons
ultim
depend
stabl
express
mhc
class
ii
upregul
costimulatori
molecul
signal
influenc
state
surround
microenviron
danger
signal
promot
develop
immun
antiinflammatori
cytokin
absenc
cytokin
promot
toler
major
differ
fviii
product
use
replac
therapi
ha
relat
glycosyl
tabl
one
obviou
differ
presenc
abo
blood
group
determin
pdfviii
exist
rhfviii
produc
mammalian
cell
cultur
furthermor
human
exhibit
inactiv
cytidin
monophosph
nacetylneuramin
acid
gene
cmah
gene
result
inabl
convert
nacetyl
neuramin
acid
nglycolylneuramin
acid
inabl
express
gal
gal
respect
result
current
market
rhfviii
product
express
wherea
nativ
human
fviii
interestingli
healthi
individu
greatli
vari
level
circul
immunoglobulin
igm
immunoglobulin
g
igg
specif
gal
gal
antibodi
may
influenc
immunogen
halflif
infus
rhfviii
antig
antibodi
inde
exploit
mechan
opson
influenza
hiv
vaccin
apc
implic
xenograft
reject
via
complementmedi
cytolysi
although
specul
suggest
dietari
predominantli
red
meat
associ
persist
circul
antibodyglycan
complex
lead
chronic
inflamm
theori
may
implic
prophylact
rhfviii
therapi
along
line
singl
studi
mice
shown
remov
nlink
glycan
associ
decreas
fviii
activ
minor
decreas
subcutan
immunogen
furthermor
studi
inact
fviii
mutant
suggest
immun
respons
fviii
independ
procoagul
function
rather
involv
intrins
element
protein
structur
role
glycosyl
fviii
immun
therefor
warrant
recognit
like
influenc
local
fviii
variou
scaveng
lectin
receptor
two
predomin
theme
repres
current
view
fviii
vwf
biodistribut
clearanc
immun
occur
liver
spleen
respect
vwf
domin
influenc
fviii
distribut
anatom
distribut
intraven
infus
protein
multivari
process
depend
bind
affin
differ
receptor
also
format
immunoglobulinand
complementmedi
immun
complex
local
coagul
factor
primarili
assess
murin
model
ha
von
willebrand
diseas
vwd
upon
intraven
infus
like
major
fviii
complex
immedi
vwf
approxim
fviii
remain
unbound
shown
rel
uptak
fviii
vwf
tissu
mass
greatest
spleen
follow
liver
suggest
higher
affin
receptormedi
clearanc
spleen
howev
sheer
size
differ
two
organ
suggest
bulk
uptak
two
factor
mediat
primarili
liver
littl
min
intraven
infus
immunofluoresc
stain
reveal
vwf
fviii
primarili
associ
kupffer
cell
liver
potenti
margin
zone
metallophil
macrophag
spleen
respect
subsequ
deplet
macrophag
use
clodronatecontain
liposom
gadolinium
chlorid
result
increas
fviii
vwf
halflif
well
decreas
fviii
immun
respons
whether
fate
unbound
fviii
parallel
fviiivwf
complex
remain
unclear
inde
fviii
infus
absenc
vwf
dramat
decreas
associ
splenic
margin
zone
possibl
suggest
increas
proteolysi
perhap
entir
differ
locat
mode
clearanc
howev
given
supraphysiolog
dose
fviii
infus
order
facilit
detect
studi
interpret
caution
investig
fviii
immunogen
anim
model
mainli
focus
spleen
rational
high
hepat
level
interleukin
il
transform
growth
factorb
tgfb
liver
promot
toler
fviiivwf
clearanc
howev
increas
evid
suggest
liver
function
secondari
lymphoid
organ
liver
sinusoid
endotheli
cell
lsec
hepat
stellat
cell
kupffer
cell
express
mhc
class
ii
costimulatori
molecul
potenti
act
apc
stimul
cell
insight
need
establish
balanc
hepat
toler
immun
role
extrasplen
fviii
clearanc
present
may
reveal
insight
initi
fviii
immun
consid
splenectom
mice
still
develop
inhibitor
similarli
immun
cell
interact
fviii
vwf
predominantli
focus
progenitorderiv
apc
may
recapitul
import
detail
nativ
apc
popul
involv
process
protein
splenic
margin
zone
repres
area
particular
import
fviii
innat
immun
compris
wide
array
antigenpres
cell
apc
optim
locat
divis
line
bloodborn
antigen
adapt
immun
cell
white
pulp
resid
apc
dc
margin
zone
mz
macrophag
mz
metallophil
macrophag
mz
b
cell
express
plethora
innat
pattern
recognit
receptor
prr
tolllik
tlr
ctype
lectin
receptor
clr
facilit
recognit
wide
array
antigen
specif
primari
cell
subset
investig
context
fviii
vwf
recent
shown
vitro
model
nearli
fviii
associ
pan
b
cell
marker
suggest
previous
unreport
potenti
role
b
cell
earli
stage
fviii
immun
respons
fviii
immun
respons
begin
intern
subsequ
proteolyt
degrad
profession
apc
follow
present
fviii
peptid
cell
majorhistocompat
molecul
mhc
class
ii
addit
layer
complex
involv
influenc
vwf
potenti
mask
fviii
intern
motif
well
appar
domin
role
vwf
fviii
clearanc
modulatori
role
vwf
fviii
immun
remain
controversi
inconsist
contrast
studi
murin
model
ha
predominantli
suggest
protect
role
vwf
fviii
immun
propos
mechan
antigen
competit
decreas
intern
apc
recent
evid
also
suggest
role
vwf
modul
present
fviii
peptid
mhc
class
ii
potenti
influenc
proteolyt
process
fviii
endocyt
vesicl
lastli
evid
alloantibodi
fviii
healthi
individu
subsequ
complement
bind
suggest
phagocytosi
may
fc
receptoror
complement
receptormedi
establish
ha
patient
inhibitor
fviii
immun
exclus
associ
high
affin
antibodi
role
nonneutr
antibodi
enhanc
immun
complex
format
opson
investig
sever
receptor
implic
bind
endocytosi
fviii
vwf
tabl
whether
receptorligand
interact
result
clearanc
present
fviii
like
depend
celltyp
tissu
surround
microenviron
better
clarif
continuum
immunogen
clearanc
liver
lymphoid
organ
therefor
need
one
clearanc
receptor
character
detail
wide
express
lipoprotein
receptorrel
protein
shown
bind
vwf
condit
shear
well
light
chain
thrombincleav
domain
fviii
absenc
vwf
mice
lack
gene
exhibit
higher
plasma
level
fviii
decreas
fviii
clearanc
direct
fviii
immunogen
model
report
two
studi
suggest
obligatori
dc
uptak
activ
cell
instead
depend
unidentifi
motif
domain
combin
defici
ldlr
show
synergist
increas
circul
fviii
level
suggest
concert
action
two
endocyt
receptor
wide
express
divers
tissuespecif
role
recogn
thirti
distinct
ligand
includ
heat
shock
protein
hsp
proteas
matrix
protein
interestingli
explor
target
dcbase
vaccin
use
hspchaperon
peptid
bind
differ
hsp
shown
activ
nuclear
factor
kappa
b
nfjb
produc
distinct
cytokin
profil
lead
inflammatori
h
h
respons
find
suggest
fviii
intern
could
provid
inflammatori
cytokin
initi
immun
respons
substanti
posttransl
addit
carbohydr
moieti
fviii
vwf
influenc
abil
intern
recognit
lectin
receptor
impact
glycosyl
circul
level
plasma
protein
demonstr
individu
differ
abo
h
blood
group
antigen
blood
type
associ
lower
vwf
antigen
level
extens
fviii
antigen
compar
nono
blood
type
due
decreas
halflif
vwf
lack
type
b
glycan
howev
specif
endocyt
receptor
respons
discrep
establish
calcium
depend
glycan
fviii
vwf
heavili
sialyl
chaintermin
residu
implic
uptak
sialic
acidbind
immunoglobulintyp
lectin
siglec
famili
specif
implic
includ
potenti
receptor
fviii
vwf
neuraminidas
treatment
abolish
bind
vwf
fviii
suggest
altern
bind
site
fviii
receptor
siglec
famili
evolv
pair
isoform
nearli
ident
ligandbind
domain
yet
elicit
diverg
immun
modul
function
particular
shown
attenu
innat
immun
respons
phagocyt
wherea
counterpart
counteract
suppress
product
proinflammatori
cytokin
respons
pathogen
similarli
colig
b
cell
receptor
togeth
use
fviiiliposom
induc
b
cell
apoptosi
lead
peripher
b
cell
toler
support
concept
siglec
repres
mechan
ensur
selftoler
complex
coupl
substanti
tissu
distribut
siglec
isoform
suggest
differenti
role
clearanc
immun
exampl
express
myeloid
lymphoid
immun
cell
spleen
lymph
node
also
liver
contrast
demonstr
asialoglycoprotein
receptor
asgpr
ctype
lectin
express
abundantli
liver
select
bind
desialyl
glycan
nonreduc
termin
bdgalactos
nnacetyldgalactosamin
complex
primarili
b
domain
fviii
hyposialyl
vwf
also
exhibit
decreas
circul
halflif
asgprdepend
mechan
asgpr
address
immunolog
perspect
wide
array
endocyt
ctype
lectin
receptor
eg
clec
famili
etc
express
dc
shown
induc
potent
helper
cell
respons
investig
respect
fviii
vwf
two
nlink
structur
domain
fviii
respect
conserv
highmannos
residu
previous
shown
facilit
uptak
macrophag
mannos
receptor
human
dc
howev
conflict
evid
shown
fviii
uptak
appear
larg
unaffect
satur
block
suggest
receptor
bind
fviii
oblig
receptor
compensatori
mechan
ensur
fviii
uptak
recent
novel
ctype
lectin
receptor
also
known
lsign
dcsignr
character
novel
receptor
bind
intern
clear
vwf
fviii
bind
express
sinusoid
endotheli
cell
liver
lymphat
system
depend
expos
high
mannos
glycan
fviii
howev
influenc
observ
mous
clearanc
studi
interact
may
role
fviii
immunogen
shown
play
protect
role
coronaviru
infect
lead
decreas
suscept
increas
viral
degrad
order
elicit
immun
peripher
toler
exogen
antigen
must
degrad
present
mhc
class
ii
howev
upon
endocytosi
molecular
basi
endosom
sort
determin
antigen
present
versu
antigen
recycl
partial
understood
furthermor
signific
bodi
literatur
regard
mhc
class
ii
present
dc
capabl
regul
less
convent
apc
remain
unclear
classic
sens
antigen
present
endosom
dc
fuse
mhc
class
iibear
endosom
load
fviiideriv
peptid
stabl
express
peptidebear
mhc
class
ii
molecul
surfac
cell
primarili
govern
matur
statu
dc
immatur
dc
ubiquitin
mhc
class
iipeptid
complex
within
endosom
vesicl
protein
complex
subsequ
deliv
lysosom
degrad
matur
dc
ubiquitin
halt
thu
inhibit
sort
mhc
class
iibear
endosom
lysosom
result
complex
deliv
stabli
express
plasma
membran
emerg
role
ubiquitin
regul
antigen
present
signific
impact
immunotherapi
target
specif
cell
type
well
control
reactiv
state
dc
lead
either
immun
toler
ultim
regul
depend
apc
matur
turn
govern
exposur
stimuli
surround
microenviron
longstand
pillar
immunolog
focus
idea
immun
system
distinguish
self
nonself
howev
model
fail
justifi
number
find
anergi
self
chang
ie
tumour
age
pregnanc
vaccin
inefficaci
without
inclus
adjuv
matzing
danger
model
present
altern
paradigm
rather
differenti
self
nonself
immun
respons
initi
danger
signal
repres
danger
damp
pathogenassoci
pamp
molecular
pattern
signal
bind
prr
tlr
nodlik
receptor
nlr
clr
rigilik
receptor
rlr
rapidli
trigger
product
proinflammatori
cytokin
detect
prr
also
provid
pivot
bridg
connect
adapt
immun
respons
activationmatur
apc
subsequ
upregul
costimulatori
molecul
essenti
compon
interact
cell
mechan
highlight
current
model
fviii
innat
respons
robust
immun
respons
elicit
matur
apc
induct
toler
mediat
immatur
apc
vitro
studi
suggest
rhfviii
either
alon
complex
vwf
present
danger
signal
human
monocytederiv
dc
suggest
addit
extern
influenc
like
associ
apc
microenviron
may
need
promot
immun
respons
inde
survey
conduct
across
ha
treatment
centr
show
signific
concern
administ
fviii
replac
therapi
presenc
inflammatori
stimuli
particularli
surgeri
would
increas
risk
inhibitor
develop
surgic
procedur
inde
associ
near
increas
inhibitor
risk
patient
howev
observ
could
confirm
murin
model
without
direct
applic
inflammatori
ligand
vaccin
also
hypothes
risk
factor
inhibitor
develop
howev
theori
challeng
clinic
evid
cite
lack
associ
vaccin
inhibitor
develop
previous
untreat
patient
moreov
shown
vaccin
human
murin
ha
model
fact
decreas
incid
inhibitor
mechan
antigen
competit
involv
chemotact
immun
divers
helper
h
cell
fundament
develop
robust
adapt
immun
respons
mainten
selftoler
breadth
function
predominantli
attribut
varieti
effector
subset
h
cell
differenti
upon
physic
interact
peptidebear
mhc
class
ii
signal
costimulatori
molecul
signal
express
antigen
present
cell
apc
polar
cell
subsequ
prolifer
influenc
magnitud
costimul
well
cytokin
surround
microenviron
signal
healthi
individu
ha
patient
without
inhibitor
shown
interferongamma
ifnc
secret
cell
indic
basal
potenti
initi
role
h
cell
fviii
immun
furthermor
studi
tcell
clone
isol
brother
mild
ha
discord
inhibitor
statu
reveal
h
h
respons
domin
earli
immun
process
transit
h
cell
parallel
matzing
danger
theori
find
suggest
import
role
proinflammatori
respons
propag
fviii
inhibitor
interestingli
overlay
mhcpresent
peptid
correspond
tand
bcell
epitop
primarili
situat
domain
previous
review
find
may
suggest
mhc
polymorph
b
cell
clone
frequent
direct
domain
somewhat
evolutionarili
conserv
manner
coincident
recent
hypothes
develop
selfreact
antibodi
acquir
thrombot
thrombocytopen
purpura
associ
molecular
mimicri
pathogenderiv
mhc
class
ii
present
peptid
inde
presenc
potenti
crossreact
low
affin
fviiireact
antibodi
circul
healthi
patient
may
suggest
inher
pathogenmedi
natur
immun
protein
may
influenc
clearanc
adapt
immun
respons
techniqu
employ
attempt
reduc
prevent
inhibitor
manifest
one
obviou
strategi
limit
presenc
proinflammatori
signal
therebi
inhibit
apc
matur
recent
shown
two
ha
mous
model
transient
coadministr
fviii
steroid
dexamethason
significantli
decreas
titr
incid
fviii
antibodi
inhibitor
result
durabl
thymic
regulatori
cell
treg
mediat
toler
addit
report
two
murin
strain
ha
administr
deplet
antibodi
increas
percentag
treg
cell
spleen
significantli
decreas
product
fviii
inhibitor
unfortun
method
immunomodul
like
accompani
albeit
small
increas
risk
opportunist
infect
young
ha
patient
anoth
immunomodulatori
approach
recent
shown
promis
murin
model
initi
immun
prime
via
oral
deliveri
plant
cell
express
fviii
antigen
target
tolerogen
mucos
environ
follow
intraven
infus
fulllength
fviii
substanti
suppress
antifviii
respons
observ
attribut
upregul
immunosuppress
cytokin
typic
liver
microenviron
tgfb
induct
fviiispecif
treg
signific
proport
research
dedic
assess
adapt
immun
respons
revers
back
toler
immun
respons
fviii
alreadi
develop
howev
need
develop
tolerogen
method
administ
fviii
well
identifi
potenti
biomark
predict
assay
determin
inhibitor
risk
children
begin
fviii
replac
therapi
immun
respons
may
initi
soon
fviii
enter
circul
highlight
critic
role
innat
immun
system
govern
balanc
clearanc
immunogen
futur
studi
prevent
inhibitor
need
address
multifactori
complex
fviii
innat
respons
microenviron
cell
inher
characterist
fviii
protein
contribut
jl
wrote
first
draft
manuscript
mg
c
h
dl
edit
manuscript
